Indeed, the same group reported that in another experiment with BNL HCC tumors treated with BNL lysate-pulsed DCs and systemic IL-12 administration, the tumor-suppressive effect required the presence of both CD4+ and CD8+ T cells, and CD8+ T cells were essential, suggesting they are potentially the critical mediators of antitumor activity in this treatment regimen (40). This evidence concerns the gene CD8A and hepatocellular carcinoma.